TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：81

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[21] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
Gomes, Jessica Ribeiro
Cruz, Marcelo Rocha S.
ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
[22] Fusion genes in EGFR-mutant lung cancer
Kobayashi, Yoshihisa
CANCER SCIENCE, 2021, 112 : 132 - 132
[23] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
Martinez-Hernandez, Maria F.
Lara-Mejia, Luis
Izquierdo-Tolosa, Carlos
Cabrera-Miranda, Luis
Arrieta, Oscar
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12)
[24] Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
Zhang, Shi-Ling
Zhang, Chan -Yuan
Chen, Yu-Qing
Li, Yu -Fa
Xie, Zhi
Zhang, Xu-Chao
Zhou, Qing
Zhong, Wen-Zhao
Huang, Jie
Sun, Hao
Zheng, Ming-Ying
Xiao, Fa-Man
Yan, Hong-Hong
Lu, Dan-Xia
Lv, Zhi-Yi
Wu, Yi-Long
Chen, Hua-Jun
Yang, Jin-Ji
JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 4620 - 4635
[25] The combined effect of afatinib and metformin on glycolytic regulation in EGFR-mutant non-small cell lung cancer
Barrios-Bernal, Pedro
Hernandez-Pedro, Norma Yanet
Soca-Chafre, Giovanny
Orozco-Morales, Mario
Arrieta, Oscar
CANCER RESEARCH, 2017, 77
[26] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
Zhang, Hongye
Wang, Ruiyu
Wang, Mingxia
Luo, Judong
Liu, Changmin
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
[27] Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Kim, Youjin
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
Sun, Jong-Mu
CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 502 - 509
[28] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Akiko Takahashi
Masahiro Seike
Mika Chiba
Satoshi Takahashi
Shinji Nakamichi
Masaru Matsumoto
Susumu Takeuchi
Yuji Minegishi
Rintaro Noro
Shinobu Kunugi
Kaoru Kubota
Akihiko Gemma
Scientific Reports, 8
[29] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Takahashi, Akiko
Seike, Masahiro
Chiba, Mika
Takahashi, Satoshi
Nakamichi, Shinji
Matsumoto, Masaru
Takeuchi, Susumu
Minegishi, Yuji
Noro, Rintaro
Kunugi, Shinobu
Kubota, Kaoru
Gemma, Akihiko
SCIENTIFIC REPORTS, 2018, 8
[30] An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Tomoshige, Koichi
Guo, Minzhe
Tsuchiya, Tomoshi
Fukazawa, Takuya
Fink-Baldauf, Iris M.
Stuart, William D.
Naomoto, Yoshio
Nagayasu, Takeshi
Maeda, Yutaka
ONCOGENE, 2018, 37 (28) : 3894 - 3908

← 1 2 3 4 5 →